CY1116992T1 - Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17 - Google Patents

Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17

Info

Publication number
CY1116992T1
CY1116992T1 CY20151101086T CY151101086T CY1116992T1 CY 1116992 T1 CY1116992 T1 CY 1116992T1 CY 20151101086 T CY20151101086 T CY 20151101086T CY 151101086 T CY151101086 T CY 151101086T CY 1116992 T1 CY1116992 T1 CY 1116992T1
Authority
CY
Cyprus
Prior art keywords
activity
treatment
ill
strengthening
prophylaxis
Prior art date
Application number
CY20151101086T
Other languages
English (en)
Inventor
Mark Ian Christie
Richard James Mead
Martyn Kim Robinson
Stephen Edward Rapecki
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34635441&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116992(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0327181A external-priority patent/GB0327181D0/en
Priority claimed from GB0417115A external-priority patent/GB0417115D0/en
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CY1116992T1 publication Critical patent/CY1116992T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια μέθοδο θεραπείας ή/και προφύλαξης της σκλήρυνσης κατά πλάκας (MS) περιέχει τη χορήγηση μιας θεραπευτικά αποτελεσματικής ποσότητας του αναστολέα της δράσης της IL-17.
CY20151101086T 2003-11-21 2015-11-30 Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17 CY1116992T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0327181A GB0327181D0 (en) 2003-11-21 2003-11-21 Biological products
GB0417115A GB0417115D0 (en) 2004-07-30 2004-07-30 Biological products
EP08008814.9A EP1983000B1 (en) 2003-11-21 2004-11-16 Method for the treatment of multiple sclerosis by inhibiting IL-17 activity

Publications (1)

Publication Number Publication Date
CY1116992T1 true CY1116992T1 (el) 2017-04-05

Family

ID=34635441

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151101086T CY1116992T1 (el) 2003-11-21 2015-11-30 Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17

Country Status (16)

Country Link
US (2) US20070269428A1 (el)
EP (3) EP1687026B1 (el)
JP (1) JP4833850B2 (el)
AT (1) ATE395083T1 (el)
AU (1) AU2004292393C1 (el)
CA (1) CA2544920C (el)
CY (1) CY1116992T1 (el)
DE (1) DE602004013825D1 (el)
DK (1) DK1983000T3 (el)
ES (2) ES2554645T3 (el)
HR (1) HRP20151210T1 (el)
HU (1) HUE026260T2 (el)
PL (1) PL1983000T3 (el)
PT (1) PT1983000E (el)
SI (1) SI1983000T1 (el)
WO (1) WO2005051422A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013141A (en) * 1960-12-30 1965-12-15 Secr Aviation Improvements in or relating to the stabilisation of electronic oscillators
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20040219150A1 (en) * 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
PL1641822T3 (pl) 2003-07-08 2013-10-31 Genentech Inc Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
SI2481753T1 (en) 2005-12-13 2018-06-29 Eli Lilly And Company Anti-IL-17 antibodies
WO2007071439A1 (en) * 2005-12-22 2007-06-28 Laboratoires Serono S.A. Soluble il-17rc variant and uses thereof
JP2009534297A (ja) 2006-03-10 2009-09-24 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆの両方に結合する抗体ならびにその使用方法
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
PE20080739A1 (es) 2006-08-11 2008-06-14 Schering Corp Anticuerpos para il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US20100331545A1 (en) 2007-10-24 2010-12-30 Nippon Chemiphar Co., Ltd. Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
KR20110025649A (ko) 2008-05-05 2011-03-10 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
MX2011003184A (es) 2008-09-29 2011-04-21 Roche Glycart Ag Anticuerpos contra il17 humana y usos de los mismos.
US20110223169A1 (en) * 2008-11-26 2011-09-15 Stern Michael E Il-17 antibody inhibitor for treating dry eye
WO2010062857A1 (en) 2008-11-26 2010-06-03 Allergan, Inc. Klk-13 antibody inhibitor for treating dry eye
RU2605318C2 (ru) 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102869678A (zh) 2009-08-27 2013-01-09 科瓦根股份公司 Il-17结合化合物及其医药用途
US20130046015A1 (en) 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) * 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
MA34907B1 (fr) 2011-01-14 2014-02-01 Ucb Pharma Sa Molécules d'anticorps se liant à il-17a et il-17f
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
AU2016315889A1 (en) 2015-09-04 2018-03-22 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
EP3150637A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Multispecific antibodies
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
GB2561352B (en) * 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
PT100379B (pt) * 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5807683A (en) * 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US5738996A (en) * 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
AU727480B2 (en) 1995-07-19 2000-12-14 Genetics Institute, Llc Human CTLA-8 and uses of CTLA-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ATE444361T1 (de) 1999-12-23 2009-10-15 Genentech Inc Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
MXPA04001187A (es) 2001-08-07 2004-07-08 Immunex Corp Receptores de interleucina-1 en el tratamiento de enfermedades.
CN101824088B (zh) * 2002-10-30 2012-05-30 健泰科生物技术公司 Il-17产生的抑制
JP4914209B2 (ja) 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
ES2354693T3 (es) 2003-06-23 2011-03-17 Genetics Institute, Llc Anticuerpos contra interleucina-22 y usos para ellos.
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
SI2481753T1 (en) 2005-12-13 2018-06-29 Eli Lilly And Company Anti-IL-17 antibodies

Also Published As

Publication number Publication date
PL1983000T3 (pl) 2016-02-29
JP2007511593A (ja) 2007-05-10
HUE026260T2 (en) 2016-06-28
PT1983000E (pt) 2015-12-30
EP2974742A1 (en) 2016-01-20
EP1983000B1 (en) 2015-09-02
DE602004013825D1 (de) 2008-06-26
AU2004292393A1 (en) 2005-06-09
ES2305879T3 (es) 2008-11-01
US20090191200A1 (en) 2009-07-30
EP1983000A2 (en) 2008-10-22
EP1687026B1 (en) 2008-05-14
AU2004292393B2 (en) 2009-10-08
AU2004292393C1 (en) 2011-08-04
WO2005051422A1 (en) 2005-06-09
EP1687026A1 (en) 2006-08-09
CA2544920A1 (en) 2005-06-09
EP1983000A3 (en) 2011-07-27
HRP20151210T1 (hr) 2015-12-04
US7931900B2 (en) 2011-04-26
DK1983000T3 (en) 2015-12-07
SI1983000T1 (sl) 2015-12-31
ES2554645T3 (es) 2015-12-22
CA2544920C (en) 2012-09-11
ATE395083T1 (de) 2008-05-15
US20070269428A1 (en) 2007-11-22
JP4833850B2 (ja) 2011-12-07

Similar Documents

Publication Publication Date Title
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
CY2016043I1 (el) Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
CY1110604T1 (el) Συνδυασμος αναστολεων πρωτεασης που εξαρτωνται απο το κυτοχρωμα ρ450
CY1109422T1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
CY1111246T1 (el) Προληψη και θεραπεια επαγομενης απο φλεγμονη και/ή ανοσοδιαμεσολαβουμενης οστικης απωλειας
CY1110133T1 (el) Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
WO2005046657A3 (en) Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
ATE406159T1 (de) Behandlung von hyperlipidämie
BRPI0416680A (pt) inibidores da forma mutante de kit
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
ATE443044T1 (de) Tace inhibitoren
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
SE0002739D0 (sv) New use
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE60130659D1 (de) Therapeutische verbindungen und verfahren